Eur Rev Med Pharmacol Sci 2022; 26 (14): 4947-4947

DOI: 10.26355/eurrev_202207_29277

Retraction Note: METTL3 promotes the progression of nasopharyngeal carcinoma through mediating M6A modification of EZH2

Q.-Z. Meng, C.-H. Cong, X.-J. Li, F. Zhu, X. Zhao, F.-W. Chen

Department of Head and Neck Surgery, Linyi Cancer Hospital, Linyi, China


The article “METTL3 promotes the progression of nasopharyngeal carcinoma through mediating M6A modification of EZH2, by Q.-Z. Meng, C.-H. Cong, X.-J. Li, F. Zhu, X. Zhao, F.-W. Chen, published in Eur Rev Med Pharmacol Sci 2020; 24 (8): 4328-4336–DOI: 10.26355/eurrev_202004_21014–PMID: 32373970” has been retracted by the authors.

After publication, several issues were raised on PubPeer about the reliability of the published results. The same authors stated that the study was not performed in accordance with the standard procedures required.

In particular, Figure 1 also presents some concerns as it does not reflect the experimental data reported in the study.

The Publisher apologizes for any inconvenience this may cause.

METTL3 promotes the progression of nasopharyngeal carcinoma through mediating M6A modification of EZH2

Free PDF Download

To cite this article

Q.-Z. Meng, C.-H. Cong, X.-J. Li, F. Zhu, X. Zhao, F.-W. Chen
Retraction Note: METTL3 promotes the progression of nasopharyngeal carcinoma through mediating M6A modification of EZH2

Eur Rev Med Pharmacol Sci
Year: 2022
Vol. 26 - N. 14
Pages: 4947-4947
DOI: 10.26355/eurrev_202207_29277